Polymeric encapsulation of a ruthenium( <scp>ii</scp> ) polypyridyl complex: from synthesis to <i>in vivo</i> studies against high-grade epithelial ovarian cancer
João P. M. António, Albert Gandioso, Fariba Némati, Nancy Soliman, Robin Vinck, Fan Sun, Carine Robert, Pierre Bürckel, Didier Decaudin, C.M. Thomas, Gilles Gasser
Abstract
performance was evaluated for the first time in mice. The experiments showed that the intravenously injected nanoparticles were well tolerated and were able to significantly improve the pharmacokinetics and biodistribution of the parent drug. Not only was the nanosystem able to promote an 18-fold increase in tumour accumulation, but it also allowed a considerable reduction of drug accumulation in vital organs, achieving, for example, reduction levels of 90% and 97% in the brain and lungs respectively. In summary, this simple and efficient one-pot procedure enables the generation of stable and predictable nanoparticles capable of improving the cellular penetration and systemic accumulation of the Ru drug in the tumour. Altogether, these results showcase the potential of covalently-loaded ruthenium polylactide nanoparticles and pave the way for its exploitation and application as a viable tool in the treatment of ovarian cancer.